Physician profile
Ross Osborn
NPI 1528042496
$1,203.37
in general payments reported to CMS, 2019-2025
19 companies · $400 in 2025
The $400 reported for 2025 was more than what 80% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2021: $16.85 · 2022: $127 · 2023: $413 · 2024: $111 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $923.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $207.92 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Axogen | $127.49 | 2023 | Avance Nerve Graft |
| Smith+Nephew, INC. | $126.50 | 2022 | |
| Novo Nordisk INC | $122.38 | 2019-2025 | Wegovy |
| Alexion Pharmaceuticals, INC. | $113.85 | 2025 | |
| Exact Sciences Corporation | $87.34 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Relievant Medsystems, INC. | $85.54 | 2023 | Intracept |
| Idorsia Pharmaceuticals US INC | $82.79 | 2023 | Quviviq |
| Inspire Medical Systems, INC. | $45.42 | 2024 | Inspire |
| Lilly USA, LLC | $30.21 | 2019 | |
| Ferring Pharmaceuticals INC. | $29.95 | 2024 | Euflexxa |
| Pacira Therapeutics, INC. | $29.03 | 2019 | |
| Glaxosmithkline, LLC. | $18.71 | 2024 | Arexvy, Shingrix |
| Assertio Therapeutics, INC. | $18.06 | 2019 | |
| Abbvie INC. | $16.85 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $16.46 | 2024 | Bevespi Aerosphere |
| Takeda Pharmaceuticals U.S.A., INC. | $16.13 | 2019 | |
| Bioventus LLC | $15.22 | 2019 | |
| Metuchen Pharmaceuticals | $13.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Osborn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.